Ragaglitazar: Pharmacokinetics and safety in subjects with or without hepatic impairment

被引：0
|
作者：
Lundholm, H
Pabst, G
Skrumsager, BK
Horak, J
机构：
来源：
DIABETES | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2009
引用
收藏
页码：A489 / A489
页数：1
相关论文
共 50 条
  • [1] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [2] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [3] PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Harisseh, Rania
    Finnegan, Beth
    Thomas, Stephane
    Legry, Vanessa
    Hum, Dean
    Marbury, Thomas C.
    Perry, Robert G.
    Wyatt, David J.
    Addy, Carol
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1391 - S1391
  • [4] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SELADELPAR IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Mao, Z.
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1320 - S1320
  • [5] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
  • [6] Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment
    Mao, Lily
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E402 - E402
  • [7] Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
    Custodio, Joseph M.
    Rhee, Martin
    Shen, Gong
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2564 - 2569
  • [8] Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers
    Zhao, QY
    Iyer, GR
    Verhaeghe, T
    Truyen, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04): : 428 - 436
  • [9] Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment
    Erik Mogalian
    Diana M. Brainard
    Anu Osinusi
    Lisa Moorehead
    Bernard Murray
    Kah Hiing John Ling
    Robert Perry
    Craig Curtis
    Eric Lawitz
    Kenneth Lasseter
    Thomas Marbury
    Anita Mathias
    [J]. Clinical Pharmacokinetics, 2018, 57 : 1449 - 1457
  • [10] PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT
    Custodio, J. M.
    Ma, G.
    Cuvin, J.
    Ting, L.
    Flaherty, J.
    Zack, J. Z.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S594 - S595
12345